The efficay of FOLFOX regimen in the treatment of 68 patients with adavanced/metastatic gastric cancer

Objective: To study the response and toxicity of the regimen of FOLFOX (oxaliplatin combined with fluorouracil and calcium folinate) in the treatment of adavanced/metastatatic gastric cancer. Motheds: 5-FU 500mg/m~2 (civ 46 hours),d1~d2 ;CF 200mg/m~2 ivdrip (2 hours),d1~d2 ;L-OHP 105mg/m~2 ivdrip (2 hours),every 3 weeks,for three cycles. Results: Sixty eight patients have been entered into the study among them CR 5 cases (7.3%), PR 28(41.2%), SD 31(42.5%), and PD 4 (5.88%) over all RR 48.5%. Median time to progress was 8.1 months and median overall survival was 14.1 months.The survival rate of 1 year was 42.2%.The Karnofsky score raised in 33 patients(48.5%) clinical benefit effect rate was 32 patients(47%). The main adverse reactions with grade 3 and 4 were neutropenia in 7 patients(10.2%), thrombocytopenia in 4 patients(5.8%), anaemia in 5 patients(7.3%), nausea/vomiting in 9 patients(13.2%), diarrhea in 3 patients(4.4%), neurotoxicity in 4 patients (5.8%). Conclusion: The regimen of oxaliplatin combined fluorouracil and calcium folinate is effective and tolerable in adavanced/metastatic gastric cancer.